Combined Gadoxetic Acid and Gadofosveset Enhanced Liver MRI: A Feasibility and Parameter Optimization Study
Peter Bannas 1,2 , Utaroh Motosugi 1 , Diego Hernando 1 , Mahdi S Rahimi 3 , James H Holmes 4 , and Scott B Reeder 1,5
Department of Radiology, University of
Wisconsin, Madison, Madison, WI, United States,
of Radiology, University Medical Center Hamburg-Eppendorf,
Hamburg, Hamburg, Germany,
of Biomedical Engineering, University of Wisconsin,
Madison, Madison, WI, United States,
MR Applications and Workflow, GE Healthcare, Madison,
WI, United States,
of Medical Physics, University of Wisconsin, Madison,
Madison, WI, United States
Gadoxetic acid enhanced hepatobiliary phase MRI is
useful for detection of hypointense liver metastases.
However, vessels and benign cavernous hemangiomas also
appear hypointense on gadoxetic acid enhanced MRI and
may be difficult to distinguish from one another. We
hypothesized that use of an intravascular contrast
agent, gadofosveset trisodium, in addition to gadoxetic
acid, may address this issue. The purpose of this work
was to demonstrate the feasibility of combined use of
these two contrast agents and to optimize MR parameters.
We concluded that combination of the two contrast agents
is feasible and worth testing in a clinical setting.
This abstract and the presentation materials are available to members only;
a login is required.